Healthy Clinical Trial
Official title:
A Phase I, Open-Label, Two-Part Study of the Effect of Multiple-Dose Evobrutinib on Transporter Substrates Digoxin, Metformin, Rosuvastatin, and Sumatriptan Pharmacokinetics in Healthy Participants
This study consists of 2 parts: Part 1 and 2. The purpose of this study is to evaluate the pharmacokinetic, safety and tolerability of multiple doses of evobrutinib on single doses of digoxin, metformin and rosuvastatin in Part-1 and sumatriptan in Part-2 of the study.
Status | Completed |
Enrollment | 40 |
Est. completion date | December 10, 2021 |
Est. primary completion date | December 10, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - Participants are overtly healthy as determined by medical evaluation, including no clinically significant abnormality identified on physical examination or laboratory evaluation and no active clinically significant disorder, condition, infection or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion - Participants have a body weight within 50.0 and 100.0 kilograms [kg] (inclusive) and body mass index within the range of 19.0 and 30.0 kilograms per square meter [kg/m^2] (inclusive) - Other protocol defined inclusion criteria could apply Exclusion Criteria: - History or presence of clinically relevant respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders, as determined by medical evaluation - Individuals with diagnosis of hemochromatosis, Wilson´s disease, alpha 1 antitrypsin deficiency, or any other chronic liver disease including Gilbert's disease will be excluded from the study - Prior history of cholecystectomy or splenectomy, and any clinically relevant surgery within 6 months prior to Screening - History of any malignancy - History of chronic or recurrent acute infection or any bacterial, viral, parasitic or fungal infections within 30 days prior to Screening and at any time between Screening and admission, or hospitalization due to infection within 6 months prior to Screening - History of shingles within 12 months prior to Screening - History of drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients; history of serious allergic reactions leading to hospitalization or any other hypersensitivity reaction in general, which may affect the safety of the participant and/or outcome of the study per the Investigator's discretion - History of alcoholism or drug abuse within 2 years prior to Screening, or positive for drugs of abuse, nicotine/cotinine or alcohol by the laboratory assays conducted during Screening and Day -1 - History of residential exposure to tuberculosis, or a positive QuantiFERON® test within 4 weeks prior to or at the time of Screening - Administration of live vaccines or live-attenuated virus vaccines within 3 months prior to Screening - Moderate or strong inhibitors or inducers of Cytochrome P450, family 3, subfamily A (CYP3A4/5) within 4 weeks prior to the first administration of study intervention - Other protocol defined exclusion criteria could apply |
Country | Name | City | State |
---|---|---|---|
Germany | Nuvisan GmbH | Neu-Ulm |
Lead Sponsor | Collaborator |
---|---|
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Transporter Cocktail | The transporter cocktail includes digoxin, metformin, and rosuvastatin. | Pre-dose through 16 hours post-dose on Days 1 and 10; 24, 36 hours post-dose on Day 2 and Day 11; 48, 60 hours post-dose on Day 3 and Day 12; 72 hours post-dose on Day 4 and Day 13 | |
Primary | Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib | Day 10, 11 and 12: 1 hours post-dose | ||
Primary | Part 2: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Sumatriptan | Pre-dose through 16 hours post-dose on Days 1 and Day 8; 24 hours post-dose on Day 2 and Day 9 | ||
Primary | Part 2: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib | Day 6, 7 and 8: 1 hours post-dose | ||
Primary | Part 1: Maximum Observed Plasma Concentration (Cmax) of Transporter Cocktail | Pre-dose through 16 hours post-dose on Days 1 and 10; 24, 36 hours post-dose on Day 2 and Day 11; 48, 60 hours post-dose on Day 3 and Day 12; 72 hours post-dose on Day 4 and Day 13 | ||
Primary | Part 1: Maximum Observed Plasma Concentration (Cmax) of Evobrutinib | Day 10, 11 and 12: 1 hours post-dose | ||
Primary | Part 2: Maximum Observed Plasma Concentration (Cmax) of Sumatriptan | Pre-dose through 16 hours post-dose on Days 1 and Day 8; 24 hours post-dose on Day 2 and Day 9 | ||
Primary | Part 2: Maximum Observed Plasma Concentration (Cmax) of Evobrutinib | Day 6, 7 and 8: 1 hours post-dose | ||
Secondary | Part 1 and Part 2: Number of Participants with Treatment Emergent Adverse Events (TEAEs) | Part 1: Up to Day 13; Part 2: Up to Day 9 | ||
Secondary | Part 1 and Part 2: Number of Participants with Treatment Emergent Adverse Events (TEAEs) by Severity | Part 1: Up to Day 13; Part 2: Up to Day 9 | ||
Secondary | Part 1 and Part 2: Number of Participants With Abnormal Changes From Baseline in Laboratory Parameters, Vital Signs and 12-Lead Electrocardiogram (ECG) Findings | Number of participants with abnormal changes from baseline in laboratory parameters, vital signs and 12-Lead electrocardiogram (ECG) findings will be reported. | Part 1: Baseline up to Day 13; Part 2: Baseline up to Day 9 | |
Secondary | Part 1: Time to Reach Maximum Plasma Concentration (Tmax) of Transporter Cocktail | Pre-dose through 16 hours post-dose on Days 1 and 10; 24, 36 hours post-dose on Day 2 and Day 11; 48, 60 hours post-dose on Day 3 and Day 12; 72 hours post-dose on Day 4 and Day 13 | ||
Secondary | Part 1: Time to Reach Maximum Plasma Concentration (Tmax) of Evobrutinib | Day 10, 11 and 12: 1 hours post-dose | ||
Secondary | Part 2: Time to Reach Maximum Plasma Concentration (Tmax) of Sumatriptan | Pre-dose through 16 hours post-dose on Days 1 and Day 8; 24 hours post-dose on Day 2 and Day 9 | ||
Secondary | Part 2: Time to Reach Maximum Plasma Concentration (Tmax) of Evobrutinib | Day 6, 7 and 8: 1 hours post-dose | ||
Secondary | Part 1: Apparent Terminal Half-Life (t1/2) of Transporter Cocktail | Pre-dose through 16 hours post-dose on Days 1 and 10; 24, 36 hours post-dose on Day 2 and Day 11; 48, 60 hours post-dose on Day 3 and Day 12; 72 hours post-dose on Day 4 and Day 13 | ||
Secondary | Part 1: Apparent Terminal Half-Life (t1/2) of Evobrutinib | Day 10, 11 and 12: 1 hours post-dose | ||
Secondary | Part 2: Apparent Terminal Half-Life (t1/2) of Sumatriptan | Pre-dose through 16 hours post-dose on Days 1 and Day 8; 24 hours post-dose on Day 2 and Day 9 | ||
Secondary | Part 2: Apparent Terminal Half-Life (t1/2) of Evobrutinib | Day 6, 7 and 8: 1 hours post-dose | ||
Secondary | Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time (AUC0-tlast) of Transporter Cocktail | Pre-dose through 16 hours post-dose on Days 1 and 10; 24, 36 hours post-dose on Day 2 and Day 11; 48, 60 hours post-dose on Day 3 and Day 12; 72 hours post-dose on Day 4 and Day 13 | ||
Secondary | Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time (AUC0-tlast) of Evobrutinib | Day 10, 11 and 12: 1 hours post-dose | ||
Secondary | Part 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time (AUC0-tlast) of Sumatriptan | Pre-dose through 16 hours post-dose on Days 1 and Day 8; 24 hours post-dose on Day 2 and Day 9 | ||
Secondary | Part 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time (AUC0-tlast) of Evobrutinib | Day 6, 7 and 8: 1 hours post-dose | ||
Secondary | Part 1: Apparent Total Body Clearance From Plasma (CL/F) of Transporter Cocktail | Pre-dose through 16 hours post-dose on Days 1 and 10; 24, 36 hours post-dose on Day 2 and Day 11; 48, 60 hours post-dose on Day 3 and Day 12; 72 hours post-dose on Day 4 and Day 13 | ||
Secondary | Part 1: Apparent Total Body Clearance From Plasma (CL/F) of Evobrutinib | Day 10, 11 and 12: 1 hours post-dose | ||
Secondary | Part 2: Apparent Total Body Clearance From Plasma (CL/F) of Sumatriptan | Pre-dose through 16 hours post-dose on Days 1 and Day 8; 24 hours post-dose on Day 2 and Day 9 | ||
Secondary | Part 2: Apparent Total Body Clearance From Plasma (CL/F) of Evobrutinib | Day 6, 7 and 8: 1 hours post-dose | ||
Secondary | Part 1: Apparent Volume of Distribution (Vz/F) During the Terminal Phase of Transporter Cocktail | Pre-dose through 16 hours post-dose on Days 1 and 10; 24, 36 hours post-dose on Day 2 and Day 11; 48, 60 hours post-dose on Day 3 and Day 12; 72 hours post-dose on Day 4 and Day 13 | ||
Secondary | Part 1: Apparent Volume of Distribution (Vz/F) During the Terminal Phase of Evobrutinib | Day 10, 11 and 12: 1 hours post-dose | ||
Secondary | Part 2: Apparent Volume of Distribution (Vz/F) During the Terminal Phase of Sumatriptan | Pre-dose through 16 hours post-dose on Days 1 and Day 8; 24 hours post-dose on Day 2 and Day 9 | ||
Secondary | Part 2: Apparent Volume of Distribution (Vz/F) During the Terminal Phase of Evobrutinib | Day 6, 7 and 8: 1 hours post-dose | ||
Secondary | Part 1: Cumulative Amount Excreted From Time Zero to the End of the Collection Interval After Dosing Dosing (Ae0-36) of Merformin | Pre-dose, 0 to 4, 4 to 8, 8 to 12 hours post-dose on Day 1 and Day 10; 12 to 24, 24 to 36 hours post-dose on Day 2 and Day 11 | ||
Secondary | Part 1: Renal Clearance (CLR) of Metformin | Pre-dose, 0 to 4, 4 to 8, 8 to 12 hours post-dose on Day 1 and Day 10; 12 to 24, 24 to 36 hours post-dose on Day 2 and Day 11 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |